Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843854 | 0.92 | KMT2A (0.48) | KMT2ALMNAMEN1CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4846315 | 0.90 | CYP3A4 (0.43) | KMT2ALMNAMEN1CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4845728 | 0.88 | LMNA (0.40) | KMT2ALMNAMEN1CYP3A4CYP2D6 | |
| SCHEMBL5256126 | 0.88 | CYP3A4 (0.47) | KMT2ALMNAMEN1CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4834992 | 0.86 | HDAC3 (0.36) | — | |
| SCHEMBL5259626 | 0.86 | CYP3A4 (0.44) | KMT2ALMNAMEN1CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL5260635 | 0.86 | — | — | |
| Trifluoroacetic Acid SCHEMBL4838285 | 0.84 | ADRB1 (0.42) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL5258414 | 0.84 | MEN1 (0.43) | KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL4843340 | 0.84 | CHEK2 (0.40) | KMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | KMT2A 2697/4885LMNA 1541/4885MEN1 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.